Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 335

1.

A Unique Panel of Patient-Derived Cutaneous Squamous Cell Carcinoma Cell Lines Provides a Preclinical Pathway for Therapeutic Testing.

Hassan S, Purdie KJ, Wang J, Harwood CA, Proby CM, Pourreyron C, Mladkova N, Nagano A, Dhayade S, Athineos D, Caley M, Mannella V, Blyth K, Inman GJ, Leigh IM.

Int J Mol Sci. 2019 Jul 12;20(14). pii: E3428. doi: 10.3390/ijms20143428.

2.

Azathioprine: friend or foe?

Leigh IM, Proby CM, Inman GJ, Harwood CA.

Br J Dermatol. 2019 May;180(5):961-963. doi: 10.1111/bjd.17345. No abstract available.

PMID:
31025740
3.

Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study.

Venables ZC, Nijsten T, Wong KF, Autier P, Broggio J, Deas A, Harwood CA, Hollestein LM, Langan SM, Morgan E, Proby CM, Rashbass J, Leigh IM.

Br J Dermatol. 2019 Sep;181(3):474-482. doi: 10.1111/bjd.17873. Epub 2019 May 6.

PMID:
30864158
4.

Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England.

Venables ZC, Autier P, Nijsten T, Wong KF, Langan SM, Rous B, Broggio J, Harwood C, Henson K, Proby CM, Rashbass J, Leigh IM.

JAMA Dermatol. 2019 Mar 1;155(3):298-306. doi: 10.1001/jamadermatol.2018.4219.

PMID:
30484823
5.

The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.

Inman GJ, Wang J, Nagano A, Alexandrov LB, Purdie KJ, Taylor RG, Sherwood V, Thomson J, Hogan S, Spender LC, South AP, Stratton M, Chelala C, Harwood CA, Proby CM, Leigh IM.

Nat Commun. 2018 Sep 10;9(1):3667. doi: 10.1038/s41467-018-06027-1.

6.

The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions.

Purdie KJ, Proby CM, Rizvi H, Griffin H, Doorbar J, Sommerlad M, Feltkamp MC, der Meijden EV, Inman GJ, South AP, Leigh IM, Harwood CA.

Front Microbiol. 2018 Aug 14;9:1806. doi: 10.3389/fmicb.2018.01806. eCollection 2018.

7.

Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity.

Hepburn LA, McHugh A, Fernandes K, Boag G, Proby CM, Leigh IM, Saville MK.

Oncotarget. 2018 May 1;9(33):23029-23046. doi: 10.18632/oncotarget.25196. eCollection 2018 May 1.

8.

Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.

McHugh A, Fernandes K, South AP, Mellerio JE, Salas-Alanís JC, Proby CM, Leigh IM, Saville MK.

Oncotarget. 2018 Apr 17;9(29):20265-20281. doi: 10.18632/oncotarget.24750. eCollection 2018 Apr 17.

9.

Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma.

Rose AM, Spender LC, Stephen C, Mitchell A, Rickaby W, Bray S, Evans AT, Dayal J, Purdie KJ, Harwood CA, Proby CM, Leigh IM, Coates PJ, Inman GJ.

Oncotarget. 2018 Feb 22;9(18):14552-14566. doi: 10.18632/oncotarget.24545. eCollection 2018 Mar 6.

10.

Genomic analysis of atypical fibroxanthoma.

Lai K, Harwood CA, Purdie KJ, Proby CM, Leigh IM, Ravi N, Mully TW, Brooks L, Sandoval PM, Rosenblum MD, Arron ST.

PLoS One. 2017 Nov 15;12(11):e0188272. doi: 10.1371/journal.pone.0188272. eCollection 2017.

11.

Keratinocyte skin cancers in the spotlight.

Nijsten T, Leigh IM.

Br J Dermatol. 2017 Aug;177(2):334-335. doi: 10.1111/bjd.15711. No abstract available.

PMID:
28833010
12.

Rhomboid family member 2 regulates cytoskeletal stress-associated Keratin 16.

Maruthappu T, Chikh A, Fell B, Delaney PJ, Brooke MA, Levet C, Moncada-Pazos A, Ishida-Yamamoto A, Blaydon D, Waseem A, Leigh IM, Freeman M, Kelsell DP.

Nat Commun. 2017 Jan 27;8:14174. doi: 10.1038/ncomms14174.

13.

Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.

Cammareri P, Rose AM, Vincent DF, Wang J, Nagano A, Libertini S, Ridgway RA, Athineos D, Coates PJ, McHugh A, Pourreyron C, Dayal JH, Larsson J, Weidlich S, Spender LC, Sapkota GP, Purdie KJ, Proby CM, Harwood CA, Leigh IM, Clevers H, Barker N, Karlsson S, Pritchard C, Marais R, Chelala C, South AP, Sansom OJ, Inman GJ.

Nat Commun. 2016 Aug 25;7:12493. doi: 10.1038/ncomms12493.

14.

WNT Signaling in Cutaneous Squamous Cell Carcinoma: A Future Treatment Strategy?

Sherwood V, Leigh IM.

J Invest Dermatol. 2016 Sep;136(9):1760-1767. doi: 10.1016/j.jid.2016.05.108. Epub 2016 Jul 19. Review.

15.

The European Union's Investment and Future Role in Dermatologic Research.

Leigh IM.

J Invest Dermatol. 2016 Jul;136(7):1307-1310. doi: 10.1016/j.jid.2016.04.034. No abstract available.

16.

MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma.

Adelmann CH, Truong KA, Liang RJ, Bansal V, Gandee L, Saporito RC, Lee W, Du L, Nicholas C, Napoli M, Mino B, South AP, Proby CM, Leigh IM, Coarfa C, Flores ER, Tsai KY.

J Invest Dermatol. 2016 Sep;136(9):1920-1924. doi: 10.1016/j.jid.2016.05.110. Epub 2016 Jun 9. No abstract available.

17.

CREBBP mutation in human cutaneous squamous cell carcinoma.

Watt SA, Purdie KJ, den Breems NY, Dimon M, Tucker S, Arron ST, McHugh A, Xue DJ, Dayal JH, Harwood CA, Leigh IM, Proby CM, South AP.

Exp Dermatol. 2016 Aug;25(8):650-1. doi: 10.1111/exd.13044. Epub 2016 Jun 30. No abstract available.

PMID:
27094574
18.

Lysyl Hydroxylase 3 Localizes to Epidermal Basement Membrane and Is Reduced in Patients with Recessive Dystrophic Epidermolysis Bullosa.

Watt SA, Dayal JH, Wright S, Riddle M, Pourreyron C, McMillan JR, Kimble RM, Prisco M, Gartner U, Warbrick E, McLean WH, Leigh IM, McGrath JA, Salas-Alanis JC, Tolar J, South AP.

PLoS One. 2015 Sep 18;10(9):e0137639. doi: 10.1371/journal.pone.0137639. eCollection 2015.

19.

Novel CARD11 Mutations in Human Cutaneous Squamous Cell Carcinoma Lead to Aberrant NF-κB Regulation.

Watt SA, Purdie KJ, den Breems NY, Dimon M, Arron ST, McHugh AT, Xue DJ, Dayal JH, Proby CM, Harwood CA, Leigh IM, South AP.

Am J Pathol. 2015 Sep;185(9):2354-63. doi: 10.1016/j.ajpath.2015.05.018. Epub 2015 Jul 26.

20.

The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.

Harwood CA, Proby CM, Inman GJ, Leigh IM.

Acta Derm Venereol. 2016 Jan;96(1):3-16. doi: 10.2340/00015555-2181. Review.

21.

Progress in skin cancer: the U.K. experience.

Leigh IM.

Br J Dermatol. 2014 Sep;171(3):443-5. doi: 10.1111/bjd.13258. No abstract available.

PMID:
25234058
22.

NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis.

South AP, Purdie KJ, Watt SA, Haldenby S, den Breems N, Dimon M, Arron ST, Kluk MJ, Aster JC, McHugh A, Xue DJ, Dayal JH, Robinson KS, Rizvi SH, Proby CM, Harwood CA, Leigh IM.

J Invest Dermatol. 2014 Oct;134(10):2630-2638. doi: 10.1038/jid.2014.154. Epub 2014 Mar 24.

23.

High levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion.

Pourreyron C, Chen M, McGrath JA, Salas-Alanis JC, South AP, Leigh IM.

Br J Dermatol. 2014 Jun;170(6):1256-65. doi: 10.1111/bjd.12715.

PMID:
24641191
24.

Type VII collagen regulates expression of OATP1B3, promotes front-to-rear polarity and increases structural organisation in 3D spheroid cultures of RDEB tumour keratinocytes.

Dayal JH, Cole CL, Pourreyron C, Watt SA, Lim YZ, Salas-Alanis JC, Murrell DF, McGrath JA, Stieger B, Jahoda C, Leigh IM, South AP.

J Cell Sci. 2014 Feb 15;127(Pt 4):740-51. doi: 10.1242/jcs.128454. Epub 2013 Dec 19.

25.

Mutations in AQP5, encoding a water-channel protein, cause autosomal-dominant diffuse nonepidermolytic palmoplantar keratoderma.

Blaydon DC, Lind LK, Plagnol V, Linton KJ, Smith FJ, Wilson NJ, McLean WH, Munro CS, South AP, Leigh IM, O'Toole EA, Lundström A, Kelsell DP.

Am J Hum Genet. 2013 Aug 8;93(2):330-5. doi: 10.1016/j.ajhg.2013.06.008. Epub 2013 Jul 3.

26.

Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.

Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, Dorfman D, Pinkus G, Weigert O, Hornick JL, Chirieac LR, Hirsch M, Oh DJ, South AP, Leigh IM, Pourreyron C, Cassidy AJ, Deangelo DJ, Weinstock DM, Krop IE, Dillon D, Brock JE, Lazar AJ, Peto M, Cho RJ, Stoeck A, Haines BB, Sathayanrayanan S, Rodig S, Aster JC.

PLoS One. 2013 Jun 18;8(6):e67306. doi: 10.1371/journal.pone.0067306. Print 2013.

27.

p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.

Matin RN, Chikh A, Chong SL, Mesher D, Graf M, Sanza' P, Senatore V, Scatolini M, Moretti F, Leigh IM, Proby CM, Costanzo A, Chiorino G, Cerio R, Harwood CA, Bergamaschi D.

J Exp Med. 2013 Mar 11;210(3):581-603. doi: 10.1084/jem.20121439. Epub 2013 Feb 18.

28.

A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population.

Harwood CA, Mesher D, McGregor JM, Mitchell L, Leedham-Green M, Raftery M, Cerio R, Leigh IM, Sasieni P, Proby CM.

Am J Transplant. 2013 Jan;13(1):119-29. doi: 10.1111/j.1600-6143.2012.04292.x. Epub 2012 Oct 16.

29.

Two mechanisms regulate keratin K15 expression in keratinocytes: role of PKC/AP-1 and FOXM1 mediated signalling.

Bose A, Teh MT, Hutchison IL, Wan H, Leigh IM, Waseem A.

PLoS One. 2012;7(6):e38599. doi: 10.1371/journal.pone.0038599. Epub 2012 Jun 27.

30.

Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.

Ng YZ, Pourreyron C, Salas-Alanis JC, Dayal JH, Cepeda-Valdes R, Yan W, Wright S, Chen M, Fine JD, Hogg FJ, McGrath JA, Murrell DF, Leigh IM, Lane EB, South AP.

Cancer Res. 2012 Jul 15;72(14):3522-34. doi: 10.1158/0008-5472.CAN-11-2996. Epub 2012 May 7.

31.

ARNT controls the expression of epidermal differentiation genes through HDAC- and EGFR-dependent pathways.

Robertson ED, Weir L, Romanowska M, Leigh IM, Panteleyev AA.

J Cell Sci. 2012 Jul 15;125(Pt 14):3320-32. doi: 10.1242/jcs.095125. Epub 2012 Apr 14.

32.

RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome.

Blaydon DC, Etheridge SL, Risk JM, Hennies HC, Gay LJ, Carroll R, Plagnol V, McRonald FE, Stevens HP, Spurr NK, Bishop DT, Ellis A, Jankowski J, Field JK, Leigh IM, South AP, Kelsell DP.

Am J Hum Genet. 2012 Feb 10;90(2):340-6. doi: 10.1016/j.ajhg.2011.12.008. Epub 2012 Jan 19.

33.

Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.

Lambert SR, Harwood CA, Purdie KJ, Gulati A, Matin RN, Romanowska M, Cerio R, Kelsell DP, Leigh IM, Proby CM.

Int J Cancer. 2012 Aug 1;131(3):E216-26. doi: 10.1002/ijc.27333. Epub 2011 Dec 21.

34.

Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.

Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, Leigh IM, Collisson EA, Gordon PB, Jakkula L, Pennypacker S, Zou Y, Sharma M, North JP, Vemula SS, Mauro TM, Neuhaus IM, Leboit PE, Hur JS, Park K, Huh N, Kwok PY, Arron ST, Massion PP, Bale AE, Haussler D, Cleaver JE, Gray JW, Spellman PT, South AP, Aster JC, Blacklow SC, Cho RJ.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17761-6. doi: 10.1073/pnas.1114669108. Epub 2011 Oct 17.

35.

Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma.

Watt SA, Pourreyron C, Purdie K, Hogan C, Cole CL, Foster N, Pratt N, Bourdon JC, Appleyard V, Murray K, Thompson AM, Mao X, Mein C, Bruckner-Tuderman L, Evans A, McGrath JA, Proby CM, Foerster J, Leigh IM, South AP.

Oncogene. 2011 Nov 17;30(46):4666-77. doi: 10.1038/onc.2011.180. Epub 2011 May 23.

36.

The reduction of water-soluble tetrazolium salt reagent on the plasma membrane of epidermal keratinocytes is oxygen dependent.

Weir L, Robertson D, Leigh IM, Panteleyev AA.

Anal Biochem. 2011 Jul 1;414(1):31-7. doi: 10.1016/j.ab.2011.02.030. Epub 2011 Feb 24.

PMID:
21354095
37.

Keratin 14-null cells as a model to test the efficacy of gene therapy approaches in epithelial cells.

D'Alessandro M, Coats SE, Jonkmann MF, Leigh IM, Lane EB.

J Invest Dermatol. 2011 Jul;131(7):1412-9. doi: 10.1038/jid.2011.19. Epub 2011 Feb 17. Erratum in: J Invest Dermatol. 2011 Jun;131(6):1388. Jonkmann, Marcel F [corrected to Jonkman, Marcel F].

38.

Hypoxia-mediated control of HIF/ARNT machinery in epidermal keratinocytes.

Weir L, Robertson D, Leigh IM, Vass JK, Panteleyev AA.

Biochim Biophys Acta. 2011 Jan;1813(1):60-72. doi: 10.1016/j.bbamcr.2010.11.014. Epub 2010 Dec 1.

39.

Tyrosine dephosphorylation is required for Bak activation in apoptosis.

Fox JL, Ismail F, Azad A, Ternette N, Leverrier S, Edelmann MJ, Kessler BM, Leigh IM, Jackson S, Storey A.

EMBO J. 2010 Nov 17;29(22):3853-68. doi: 10.1038/emboj.2010.244. Epub 2010 Oct 19.

40.

No evidence that human papillomavirus is responsible for the aggressive nature of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.

Purdie KJ, Pourreyron C, Fassihi H, Cepeda-Valdes R, Frew JW, Volz A, Weissenborn SJ, Pfister H, Proby CM, Bruckner-Tuderman L, Murrell DF, Salas-Alanis JC, McGrath JA, Leigh IM, Harwood CA, South AP.

J Invest Dermatol. 2010 Dec;130(12):2853-5. doi: 10.1038/jid.2010.243. Epub 2010 Aug 26. No abstract available.

41.

High-resolution genomic profiling of human papillomavirus-associated vulval neoplasia.

Purdie KJ, Harwood CA, Gibbon K, Chaplin T, Young BD, Cazier JB, Singh N, Leigh IM, Proby CM.

Br J Cancer. 2010 Mar 16;102(6):1044-51. doi: 10.1038/sj.bjc.6605589.

42.

External anogenital premalignant and malignant disease.

Gibbon KL, Ekeowa-Anderson AL, Leigh IM.

Cancer Treat Res. 2009;146:279-98. doi: 10.1007/978-0-387-78574-5_23. Review. No abstract available.

PMID:
19415210
43.

Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs.

Purdie KJ, Harwood CA, Gulati A, Chaplin T, Lambert SR, Cerio R, Kelly GP, Cazier JB, Young BD, Leigh IM, Proby CM.

J Invest Dermatol. 2009 Jun;129(6):1562-8. doi: 10.1038/jid.2008.408. Epub 2009 Jan 8.

44.

Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.

Wong T, Gammon L, Liu L, Mellerio JE, Dopping-Hepenstal PJ, Pacy J, Elia G, Jeffery R, Leigh IM, Navsaria H, McGrath JA.

J Invest Dermatol. 2008 Sep;128(9):2179-89. doi: 10.1038/jid.2008.78. Epub 2008 Apr 3.

45.

An altered keratinocyte phenotype in oral submucous fibrosis: correlation of keratin K17 expression with disease severity.

Lalli A, Tilakaratne WM, Ariyawardana A, Fitchett C, Leigh IM, Hagi-Pavli E, Cruchley AT, Parkinson EK, Teh MT, Fortune F, Waseem A.

J Oral Pathol Med. 2008 Apr;37(4):211-20. doi: 10.1111/j.1600-0714.2007.00609.x. Epub 2008 Jan 17.

PMID:
18205743
46.
47.

HPV8 early genes modulate differentiation and cell cycle of primary human adult keratinocytes.

Akgül B, Ghali L, Davies D, Pfister H, Leigh IM, Storey A.

Exp Dermatol. 2007 Jul;16(7):590-9.

48.

A comparison of tissue-engineered hyaluronic acid dermal matrices in a human wound model.

Price RD, Das-Gupta V, Leigh IM, Navsaria HA.

Tissue Eng. 2006 Oct;12(10):2985-95.

PMID:
17518666
49.

Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression.

Pourreyron C, Cox G, Mao X, Volz A, Baksh N, Wong T, Fassihi H, Arita K, O'Toole EA, Ocampo-Candiani J, Chen M, Hart IR, Bruckner-Tuderman L, Salas-Alanis JC, McGrath JA, Leigh IM, South AP.

J Invest Dermatol. 2007 Oct;127(10):2438-44. Epub 2007 May 10.

50.

Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.

Purdie KJ, Lambert SR, Teh MT, Chaplin T, Molloy G, Raghavan M, Kelsell DP, Leigh IM, Harwood CA, Proby CM, Young BD.

Genes Chromosomes Cancer. 2007 Jul;46(7):661-9.

Supplemental Content

Loading ...
Support Center